Hepion screens first subject in Phase IIb trial of NASH drug

Hepion Pharmaceuticals has screened the first participant in the Phase IIb ASCEND-NASH clinical trial of its drug candidate, rencofilstat, to treat non-alcoholic steatohepatitis (NASH).